27876084|t|A trial to determine whether septic shock - reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial
27876084|a|Current pediatric septic shock resuscitation guidelines from the American College of Critical Care Medicine focus on the early and goal-directed administration of intravascular fluid followed by vasoactive medication infusions for persistent and fluid-refractory shock. However, accumulating adult and pediatric data suggest that excessive fluid administration is associated with worse patient outcomes and even increased risk of death. The optimal amount of intravascular fluid required in early pediatric septic shock resuscitation prior to the initiation of vasoactive support remains unanswered. The SQUEEZE Pilot Trial is a pragmatic, two-arm, parallel-group, open-label, prospective pilot randomized controlled trial. Participants are children aged 29 days to under 18 years with suspected or confirmed septic shock and a need for ongoing resuscitation. Eligible participants are enrolled under an exception to consent process and randomly assigned via concealed allocation to either the Usual Care (control) or Fluid Sparing (intervention) resuscitation strategy. The primary objective of this pilot trial is to determine feasibility, based on the ability to enroll participants and to adhere to the study protocol. The primary outcome measure by which success will be determined is participant enrollment rate ("pass" defined as at least two participants / site / month, recognizing that enrollment may be slower during the run-in phase). Secondary objectives include assessing (1) appropriateness of eligibility criteria, and (2) completeness of clinical outcomes to inform the endpoints for the planned multisite trial. To support the nested translational study, SQUEEZE-D, we will also evaluate the feasibility of describing cell-free DNA (a procoagulant molecule with prognostic utility) in blood samples obtained from children enrolled into the SQUEEZE Pilot Trial at baseline and at 24 h. The optimal degree of fluid resuscitation and the timing of initiation of vasoactive support in order to achieve recommended therapeutic targets in children with septic shock remains unanswered. No prospective study to date has examined this important question for children in developed countries including Canada. Recruitment for the SQUEEZE Pilot Trial opened on 6 January 2014. Findings will inform the feasibility of the planned multicenter trial to answer our overall research question. ClinicalTrials.gov Identifier NCT01973907, registered on 23 October 2013.
27876084	2	7	trial	T062	C0008976
27876084	29	41	septic shock	T046	C0036983
27876084	44	52	reversal	T169	C0443290
27876084	56	63	quicker	T080	C0456962
27876084	67	76	pediatric	T080	C1521725
27876084	77	85	patients	T101	C0030705
27876084	86	96	randomized	T062	C0034656
27876084	103	108	early	T079	C1279919
27876084	109	145	goal-directed fluid-sparing strategy	T061	C1271494
27876084	153	163	usual care	T058	C0511425
27876084	165	172	SQUEEZE	T062	C0008976
27876084	175	189	study protocol	T170	C2348563
27876084	196	229	pilot randomized controlled trial	T062	C0206035
27876084	230	237	Current	T079	C0521116
27876084	238	247	pediatric	T080	C1521725
27876084	248	260	septic shock	T046	C0036983
27876084	261	274	resuscitation	T061	C0035273
27876084	275	285	guidelines	T170	C0162791
27876084	295	337	American College of Critical Care Medicine	T093	C1708333
27876084	351	356	early	T079	C1279919
27876084	361	389	goal-directed administration	T061	C1271494
27876084	393	406	intravascular	T082	C0442123
27876084	407	412	fluid	T031	C0005889
27876084	425	435	vasoactive	T080	C1980011
27876084	436	446	medication	T121	C0013227
27876084	447	456	infusions	T061	C0574032
27876084	461	471	persistent	T079	C0205322
27876084	476	498	fluid-refractory shock	T047	C0349412
27876084	509	521	accumulating	T033	C4055506
27876084	522	527	adult	T100	C0001675
27876084	532	541	pediatric	T080	C1521725
27876084	542	546	data	T078	C1511726
27876084	560	569	excessive	T080	C0442802
27876084	570	590	fluid administration	T061	C0522792
27876084	610	615	worse	T033	C1457868
27876084	616	623	patient	T101	C0030705
27876084	624	632	outcomes	T169	C1274040
27876084	642	665	increased risk of death	T033	C2749787
27876084	671	685	optimal amount	T081	C1265611
27876084	689	702	intravascular	T082	C0442123
27876084	703	708	fluid	T031	C0005889
27876084	721	726	early	T079	C1279919
27876084	727	736	pediatric	T080	C1521725
27876084	737	749	septic shock	T046	C0036983
27876084	750	763	resuscitation	T061	C0035273
27876084	777	787	initiation	T169	C1704686
27876084	791	809	vasoactive support	T080	C1980011
27876084	834	853	SQUEEZE Pilot Trial	T062	C0008976
27876084	859	868	pragmatic	T054	C0871858
27876084	870	877	two-arm	T062	C0242481
27876084	879	893	parallel-group	T062	C2826345
27876084	895	905	open-label	T062	C1709323
27876084	907	952	prospective pilot randomized controlled trial	T062	C0206035
27876084	954	966	Participants	T098	C0679646
27876084	971	979	children	T100	C0008059
27876084	980	984	aged	T032	C0001779
27876084	988	992	days	T079	C0439228
27876084	1005	1010	years	T079	C0439234
27876084	1016	1025	suspected	T078	C0750491
27876084	1029	1038	confirmed	T033	C0750484
27876084	1039	1051	septic shock	T046	C0036983
27876084	1075	1088	resuscitation	T061	C0035273
27876084	1099	1111	participants	T098	C0679646
27876084	1116	1124	enrolled	T058	C1516879
27876084	1134	1143	exception	T077	C1705847
27876084	1147	1154	consent	T169	C1511481
27876084	1155	1162	process	T067	C1522240
27876084	1167	1175	randomly	T080	C0439605
27876084	1176	1184	assigned	T169	C1516050
27876084	1189	1198	concealed	T080	C0443189
27876084	1199	1209	allocation	T052	C1706778
27876084	1224	1234	Usual Care	T058	C0511425
27876084	1236	1243	control	T096	C0009932
27876084	1248	1299	Fluid Sparing (intervention) resuscitation strategy	T061	C0035273
27876084	1305	1312	primary	T080	C0205225
27876084	1313	1322	objective	T170	C0018017
27876084	1331	1342	pilot trial	T062	C0008976
27876084	1359	1370	feasibility	T062,T170	C0015730
27876084	1396	1402	enroll	T058	C1516879
27876084	1403	1415	participants	T098	C0679646
27876084	1437	1451	study protocol	T170	C2348563
27876084	1457	1480	primary outcome measure	T080	C3274433
27876084	1490	1497	success	T080	C0679864
27876084	1520	1531	participant	T098	C0679646
27876084	1532	1542	enrollment	T058	C1516879
27876084	1543	1547	rate	T081	C1521828
27876084	1580	1592	participants	T098	C0679646
27876084	1595	1599	site	T082	C0205145
27876084	1602	1607	month	T079	C0439231
27876084	1626	1636	enrollment	T058	C1516879
27876084	1687	1697	objectives	T170	C0018017
27876084	1720	1735	appropriateness	T080	C0814634
27876084	1739	1759	eligibility criteria	T080	C1516637
27876084	1769	1781	completeness	T080	C0439812
27876084	1785	1802	clinical outcomes	T169	C1274040
27876084	1817	1826	endpoints	T080	C2349179
27876084	1835	1842	planned	T169	C1301732
27876084	1843	1858	multisite trial	T062	C0206012
27876084	1875	1901	nested translational study	T062	C0008972
27876084	1903	1912	SQUEEZE-D	T062	C0008972
27876084	1940	1951	feasibility	T062,T170	C0015730
27876084	1966	1979	cell-free DNA	T114	C4289789
27876084	1983	2004	procoagulant molecule	T116,T123	C1292267
27876084	2010	2028	prognostic utility	T170	C0220901
27876084	2033	2046	blood samples	T031	C0178913
27876084	2061	2069	children	T100	C0008059
27876084	2070	2078	enrolled	T058	C1516879
27876084	2088	2107	SQUEEZE Pilot Trial	T062	C0008976
27876084	2111	2119	baseline	T081	C1442488
27876084	2145	2151	degree	T081	C0449286
27876084	2155	2160	fluid	T031	C0005889
27876084	2161	2174	resuscitation	T061	C0035273
27876084	2183	2189	timing	T079	C0449243
27876084	2193	2203	initiation	T169	C1704686
27876084	2207	2225	vasoactive support	T080	C1980011
27876084	2258	2269	therapeutic	T169	C0302350
27876084	2270	2277	targets	T169	C1521840
27876084	2281	2289	children	T100	C0008059
27876084	2295	2307	septic shock	T046	C0036983
27876084	2331	2348	prospective study	T062	C0033522
27876084	2352	2356	date	T079	C0011008
27876084	2385	2393	question	T170	C1522634
27876084	2398	2406	children	T100	C0008059
27876084	2410	2429	developed countries	T080	C0282613
27876084	2440	2446	Canada	T083	C0006823
27876084	2448	2459	Recruitment	T052	C2949735
27876084	2468	2487	SQUEEZE Pilot Trial	T062	C0008976
27876084	2488	2494	opened	T033	C3483819
27876084	2514	2522	Findings	T033	C0243095
27876084	2539	2550	feasibility	T062,T170	C0015730
27876084	2558	2565	planned	T169	C1301732
27876084	2566	2583	multicenter trial	T062	C0206012
27876084	2598	2605	overall	T080	C1561607
27876084	2606	2623	research question	T078	C0681799